RIP kinase

Receptor-interacting protein kinases;RIPK



Receptor interacting protein 2 (RIP2), a serine/threonine kinase, is an adaptor molecule of NOD1 and NOD2, and genetic variation in this receptor is known to be associated with the severity of allergic asthma in children.

Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. WEHI-345, a selective RIPK2 kinase inhibitor, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement.

Receptor interacting protein kinase 3 (RIPK3) is a cytosolic master regulator of necroptosis. RIPK3 has an active serine/threonine kinase domain at the N-terminus, and a unique protein-protein interaction domain called the RIP homotypic interaction motif (RHIM) at the C-terminus. Both kinase activity and RHIM are indispensable for necroptosis. RIPK3 interacts with other RHIM-containing proteins such as RIPK1, Toll/interleukin-1 (IL-1) receptor domain-containing adaptor protein inducing interferon β (TRIF) or DNA-dependent activator of interferon regulatory factor (DAI). RIPK3 induces necroptosis, a type of regulated necrosis, through its kinase domain and RHIM.

RIP kinase Inhibitors & Modulators

GSK'481
(GSK481) Cat. No.: HY-100131

Bioactivity: GSK'481 can inhibit RIP1 WT S166 phosphorylation in human vs mouse plasmids overexpressed in HEK293T cells.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



GSK'872
(GSK872) Cat. No.: HY-101872

Bioactivity: GSK'872 is a **RIPK3** inhibitor, which binds RIP3 kinase domain with an IC_{50} of 1.8 nM, and inhibits kinase activity with an IC_{50} of 1.3 nM.

Purity: 99.65%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



GSK2593074A
(GSK'074) Cat. No.: HY-122909

Bioactivity: GSK2593074A (GSK'074) is a **necroptosis** inhibitor with dual targeting ability to both **RIP1** and **RIP3** [1].

Purity: >98%
Clinical Data: No Development Reported
Size:



GSK2982772
Cat. No.: HY-101760

Bioactivity: GSK2982772 is a potent and ATP competitive **RIP1** inhibitor with an IC_{50} of 16 nM.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



GSK583
Cat. No.: HY-100339

Bioactivity: GSK583 is a highly potent and selective inhibitor of **RIP2 Kinase**, with IC_{50} of 5 nM.

Purity: 98.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



GSK963
Cat. No.: HY-103028A

Bioactivity: GSK963 is a chiral, highly potent and selective inhibitor of **RIP1 kinase**, with an IC_{50} of 29 nM. GSK963 is a selective and potent inhibitor of necroptosis in murine and human cells in vitro [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



HS-1371
Cat. No.: HY-114349

Bioactivity: HS-1371 is a potent and ATP-competitive **receptor-interacting protein kinase 3 (RIP3)** inhibitor with an IC_{50} of 20.8nM [1].

Purity: 98.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Nec-4
Cat. No.: HY-18900

Bioactivity: Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 **(RIP1)** inhibitor, with an IC_{50} of 2.6 μM, K_i of 0.46 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Necrostatin-1
(Nec-1) Cat. No.: HY-15760

Bioactivity: Necrostatin-1 (Nec-1) is a potent, selective and cell-permeable **necroptosis** inhibitor with an EC_{50} of 490 nM in Jurkat cells. It acts by inhibiting the death domain kinase RIP (**RIP1**) in the necroptosis pathway.

Purity: 99.20%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



RIP2 kinase inhibitor 1
Cat. No.: HY-19764

Bioactivity: RIP2 kinase inhibitor 1 is a receptor interacting protein-2 (**RIP2**) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.

Purity: 98.11%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



RIP2 kinase inhibitor 2

Cat. No.: HY-19761

Bioactivity: RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (**RIP2**) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



RIPA-56

Cat. No.: HY-101032

Bioactivity: RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (**RIP1**) with an $\mathbf{IC_{50}}$ of 13 nM.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg



WEHI-345

Cat. No.: HY-18937

Bioactivity: WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM. IC50 value: 0.13 μM Target: RIPK2 in vitro: WEHI-345 is a selective RIPK2 kinase inhibitor, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement. WEHI-345 is an ATP analogue and was therefore...

Purity: 98.56%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg